key: cord-0729381-v9twkpbi
authors: Cakir, Merve; Obernier, Kirsten; Forget, Antoine; Krogan, Nevan J.
title: Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
date: 2021-09-14
journal: mSystems
DOI: 10.1128/msystems.00388-21
sha: 37fb11f10939b8475fd6ebf23a39851616e2b6c6
doc_id: 729381
cord_uid: v9twkpbi

Current epidemics, such as AIDS or flu, and the emergence of new threatening pathogens, such as the one causing the current coronavirus disease 2019 (COVID-19) pandemic, represent major global health challenges. While vaccination is an important part of the arsenal to counter the spread of viral diseases, it presents limitations and needs to be complemented by efficient therapeutic solutions. Intricate knowledge of host-pathogen interactions is a powerful tool to identify host-dependent vulnerabilities that can be exploited to dampen viral replication. Such host-directed antiviral therapies are promising and are less prone to the development of drug-resistant viral strains. Here, we first describe proteomics-based strategies that allow the rapid characterization of host-pathogen interactions. We then discuss how such data can be exploited to help prioritize compounds with potential host-directed antiviral activity that can be tested in preclinical models.

V iral diseases represent a major cause of mortality across the world and can devastate our global health systems (1) . The current coronavirus disease 2019 (COVID- 19) pandemic illustrates the need to develop innovative tools that allow the rapid identification of potential therapies when new viral epidemics occur. Approaches exploiting mRNA have allowed the development of effective vaccines against COVID-19 at record speed (2) (3) (4) (5) (6) . While vaccines are often the most efficient approach to control viral infections in the long term, it needs time to be administered to the general population, does not provide 100% antiviral efficiency, and cannot be administered to every patient (7) . Therefore, it is critical to develop antiviral therapies as a measure to treat patients suffering from viral diseases when prevention fails. However, drug development is often a process too slow to be readily deployable to an emerging outbreak of disease. It is therefore key to establish new methods that facilitate the rapid identification of antiviral compounds to treat viral infections in vulnerable patients (8) .

To date, most FDA-approved antiviral drugs target viral proteins involved in its replication cycle (9) . However, a major challenge of these antiviral compounds is that they facilitate the common emergence of drug-resistant viral strains (10, 11) and are effective only against particular infections, hampering the possibility of pan-viral efficacies and repurposing against emerging new diseases. Viruses rely on the host cellular machinery to ensure their replication. Host-directed therapies (HDTs) take advantage of this dependency and attempt to disrupt the virus replication cycle by inhibiting essential host factors (12) (13) (14) (15) (16) (17) . Host genes that viruses rely on for survival have a low propensity to mutate within the treatment time frame, and adaptation of the virus to compensatory host factors likely occurs only under long-term selection pressure of a host-directed antiviral. Moreover, different viruses may share dependencies of specific host proteins or functions. Therefore, targeting the host proteins required for viral replication is a viable and innovative strategy that can avoid resistance and lead to potentially broad-spectrum therapeutics as families of viruses often exploit common cellular pathways and processes. However, HDTs require in-depth knowledge of virus-host interactions and their biological significance to virus replication. New approaches are aimed at identifying these cellular host factors, and proteomics approaches provide a powerful tool to elucidate the direct physical interactions between host and pathogen as well as perturbations to the host cells proteome caused by viral infection. Using functional genomics, the anti-or proviral function as well as the endogenous function of the identified host factors can be assessed. For example, the role of host factors on viral replication can be studied by knocking out individual host factors using CRISPR followed by viral infection. Only host factors that are identified as host dependency factors without altering critical endogenous molecular functions are suitable for pharmacological inhibition for HDT. Examples of successful HDT include the use of C-C chemokine receptor type 5 (CCR5) antagonists for the human immunodeficiency virus (HIV), cyclosporine for influenza A virus (IAV) and anti-claudin-1 and antioccludin monoclonal antibodies for hepatitis C virus (HCV). CCR5 antagonists inhibit HIV cell entry by blocking the interaction of the HIV type 1 (HIV-1) gp120 envelope glycoprotein with one of its host coreceptors, CCR5 (18, 19) . Cyclosporine targets the interaction between influenza virus protein M1 and the host factor cyclophilin A, increasing the ability of cyclophilin A to inhibit M1 (20) . It has also been shown that cyclosporine can inhibit nuclear export of viral RNA (21) . HCV can bind to the tight junction protein claudin-1 and occludin to enter cells, and monoclonal antibodies against those two proteins have been shown to decrease HCV infection (22, 23) . However, despite these examples, great effort has not been placed on therapeutically targeting the host in an effort to combat infectious disease.

Recently, massive efforts to identify therapeutic strategies to manage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, have been undertaken. Understanding how SARS-CoV-2 interacts with the host cellular machinery and the identification of host dependency factors have led to the identification of promising drugs and investigational new drugs (INDs) that could be repurposed for HDT (24, 25) . In this minireview, we will discuss how proteomics and systems biology approaches can streamline the discovery of antiviral host-directed therapies ( Fig. 1 ). We will first give an overview of the most commonly used proteomics approaches to (i) map viral protein interactions with host proteins, (ii) map the global effects of viral infection on cellular signaling, and (iii) determine structure function. We will then describe how such proteomic data can be used to direct drug repurposing or new drug discovery.

The identification of putative key host factors is crucial to drive the development of innovative HDTs. Proteomics approaches present many advantages to do so, as they allow the unbiased mapping of protein-protein interactions (PPIs) and signaling perturbations due to infection, and ultimately enable structure-function studies. Coupled with other systems biology approaches, proteomic data are particularly suited to guide the discovery of innovative antiviral therapeutic strategies using HDTs (26) . This section briefly gives an overview of mass spectrometry (MS) methods used to study virus-host interactions (reviewed extensively in references 27 and 28).

Proteomics approaches for protein-protein interaction mapping. Affinity purification-mass spectrometry (AP-MS) and proximity-dependent labeling (PDL) permit the extensive mapping of PPI networks and can uncover host machinery that viral proteins associate with and potentially hijack. Such approaches have successfully been used to map Zika virus, herpesvirus, HIV-1, and SARS-CoV-2 virus-host PPIs and give critical insights into identifying important host factors for those viruses (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) .

AP-MS is a widely used method to characterize the interactors of epitope-tagged bait proteins (41) . Tagged viral proteins are expressed in host cells and purified with their bound interactors that are subsequently identified by MS. AP-MS allows the rapid, quantitative, and unbiased identification of multiple host interactors of a viral protein in a single experiment. While AP-MS presents some limitations, including the potential loss of weak interactions or the difficulty to recover membrane proteins, its ease of use and scalability permit it to generate extensive mapping of PPIs in a very short time. This is exemplified by the timely description of the SARS-CoV-2 interaction network only a few months after the pandemic outbreak (29) , an immense undertaking that has been possible due to a massive collaborative effort (42) . When designing AP-MS experiments, it is also important to consider that N-or C-terminal tagging can have an effect on protein function, requiring testing the functional status of tagged proteins. Finally, AP-MS also does not discriminate between direct and indirect interactions. However, this can be addressed by coupling AP-MS with cross-linking reagents, which allows the identification of direct interactions (see "Structure MS" section below) (43) (44) (45) .

PDL uses enzymes fused to the protein of interest to biotinylate interactors in close proximity (46, 47) . Two classes of enzymes are mainly used: promiscuous biotin protein ligases (BirA/BioID/TurboID) (48) (49) (50) or engineered ascorbic acid peroxidases (APEX) (51) (52) (53) . In both cases, upon addition of their substrate, proteins in a 10-to 20-nm range are biotinylated and can be subsequently purified using streptavidin resin followed by identification using MS. The main advantages of the PDL approach, compared to AP-MS, resides in its ability to detect transient or weak interactions as well as membrane-bound partners. Moreover, due to the covalent labeling of interacting proteins by biotin, lysis and purification can be performed under stringent conditions to reduce background. PDL can also provide information on the subcellular localization of the identified PPI by the proximal labeling of organelle-specific proteins or specific use of spatial references (54) .

Global proteomics approaches. Viruses trigger global changes in the molecular landscape of infected cells in order to ensure their replication and evasion from the cell's innate immunity. Measurements of cell signaling rewiring, regulation of protein levels, and changes to transcription upon viral infection provide a holistic understanding of the mechanisms at play during infection.

High-throughput characterization of posttranslational modifications (PTMs) especially offer valuable insight into the biology of viral infections, as PTMs have critical roles in many different aspects of infection that have both proviral (inhibiting interferon response or promoting viral replication and assembly) and antiviral consequences (degrading viral proteins through ubiquitination or inactivating them through changes in PTMs) (55, 56) . Various studies also revealed how the dynamic interplay between different PTMs (such as phosphorylation, ubiquitination, and SUMOylation) regulates processes like pathogen-sensing pathways and innate immune signaling, underscoring the importance of characterizing the dynamics of these modifications upon infection (57) (58) (59) (60) . In particular, phosphoproteomic profiling of infected cells allows identification of changes in kinase activity over the time course of infection (61) (62) (63) . Kinases represent attractive drug targets, as many kinase-regulating drugs and compounds have been developed for the treatment of various diseases, and numerous studies have shown that host kinases can regulate various steps of the virus replication cycle (16) . Recent improvements in phosphopeptide enrichment using ion metal affinity or ion-exchange chromatography coupled to MS now allows for the routine identification of tens of thousands of phosphorylated peptides in a single experiment (64) (65) (66) . Moreover, computational methods to quantify and localize the phosphorylation sites have also greatly improved, leading to the possibility to infer many kinases' activity using growing kinase-substrate relationship databases (67) (68) (69) . Other PTMs such as ubiquitination or acetylation can be assessed using MS (70) (71) (72) (73) , and an integrative analysis of multiple PTMs with protein abundance can provide insight into the cross talk between different signaling events (74) . Changes in PTM abundance upon infection can lead to the identification of pathways or enzymes controlling such PTMs and targetable using HDTs.

Global protein abundance also provides valuable insights as host proteins can be up-or downregulated after virus infection and show deregulation of pathways that could be therapeutically actionable. Classic global proteomics approaches using mass spectrometry have successfully been used to characterize changes in protein levels following infection (74) (75) (76) . Recent studies combined global proteomics approaches and thermal proteome profiling (TPP) to assess changes in protein levels and activity during SARS-CoV-2 and cytomegalovirus infection (77, 78) . Thermal shift assay approaches, such as cellular thermal shift assays (CESTA), could also be used to understand antiviral compound's molecular consequences and targets in relevant cell models (79) .

Finally, viruses induce reorganization of subcellular structure and organelles of infected cells to promote replication. Such spatial changes in protein levels and organization can be probed using the methodologies discussed here and reviewed in detail by Jean Beltran et al. (80) . Briefly, organelle fractionation followed by MS (81, 82) or proximity-based biotinylation (83-87) have been used in numerous studies to assess subcellular compartment content and are particularly suited to study how viruses reshape cell proteome landscape.

Structure MS. Cross-linking mass spectrometry (XL-MS) uses chemical cross-linkers to covalently bridge reactive amino acid residues in close proximity (43, 88, 89) . Pairs of linked peptides can then be identified by MS. This technique can therefore provide not only PPI information but structural insights on intra-and intermolecular interaction surfaces as well. Combined with dedicated structural approaches such as cryo-electron microscopy (cryo-EM) and structure predictions through deep learning systems such as AlphaFold (Deepmind), XL-MS facilitates and validates structure determination of challenging protein complexes (90, 91) . Cross-linking can also be performed in combination with affinity purification of protein baits in order to determine direct interactions between copurifying proteins and improve AP-MS resolution (92) .

Hydrogen/deuterium exchange mass spectrometry (H/DX-MS) allows the study of protein conformation for individual proteins or protein complexes. H/DX-MS measures changes in mass associated with the exchange between deuterium isotopes and hydrogens of the protein backbone amides (93, 94) . The rate of the exchange is dependent on the conformational state of the protein and surface accessibility. Therefore, H/DX-MS is useful to probe folding dynamics, allosteric changes, protein conformation, and binding sites (95) (96) (97) (98) (99) . Applications of H/DX-MS include the characterization of protein structure changes in response to PTMs or characterization of the binding of small molecules to proteins.

Drug repurposing can offer an expedited timeline to bring host-directed antiviral therapies into clinical settings in a cost-effective and timely manner in comparison to traditional drug discovery, as designing a new compound, characterizing its efficacy, and demonstrating its safety can be a slow and resource-intensive process with a higher risk of failure. Successful applications of repurposing have occasionally been driven by observations of unexpected consequences of drugs, such as the discovery of minoxidil's effects on hair growth when it was being tested for hypertension and the approval of sildenafil for erectile dysfunction treatment even though it was originally in trial for angina treatment (100, 101) . Following advances in various omics technologies and development of computational methodologies, data-driven approaches are also increasingly being used to gain valuable insight into identifying the most suitable candidates for repurposing.

The proteomics approaches described above are suited for repurposing studies, as they enable the identification of host factors and pathways that are hijacked and rewired during infection. Combined with functional genetics to identify host dependency factors, the data obtained provide a rich list of potential targets for therapeutic interventions. Once targets are identified, several databases can be used to determine their druggability and identify existing chemical matter, ranging from preclinical compounds to INDs and FDA-approved drugs. These databases are also used to gain extensive information on relevant drugs, as they catalog their protein targets, structures, chemical properties, or clinical profiles (102) . DrugBank is a frequently used database across many studies that make use of drug-target interaction networks and provides detailed information on various properties of more than 14,000 drugs, including their targets, pharmacodynamics, mechanism of action, and toxicity (103) . Other valuable resources include DGIdb (the Drug-Gene Interaction Database), ChEMBL, and PharmGKB (the Pharmacogenomics Knowledgebase). DGIdb characterizes the druggable genome by curating information from various drug-and gene-related databases for more than 10,000 drugs and 40,000 genes and annotates their associated drug-target relationships (104) . ChEMBL is based on the curation of more than 80,000 publications and offers a broader scope of nearly 2.1 million compounds by providing genomic and chemical data on bioactive drug-like small molecules (105) . For studies with a pharmacogenomics focus, PharmGKB is a relevant resource as it curates knowledge on gene-drug associations and effects of genetic variation on drug response (106) . Selection of a particular database is typically tailored to specific aims of the approach, and frequently multiple resources are integrated with each other to increase the coverage of drug-gene interaction networks built to connect host factors to relevant drugs.

Several studies have applied proteomics technologies to reveal virus-host interactions and searched for direct interactions between these host factors and drugs, with the aim to identify compounds or drugs that inhibit processes the virus relies on. Studies with this strategy include the work by Dapat et al. on respiratory syncytial virus, where the authors created its interaction network by integrating host factors identified across nine proteomics and seven transcriptomics studies (107) . DrugBank was then used to query drugs targeting this network, revealing 177 FDA-approved drugs targeting 78 host proteins belonging to various categories such as anti-infective and anticancer agents. An AP-MS study by Gordon et al. identified 332 human proteins interacting with 26 SARS-CoV-2 proteins, revealing various complexes and processes hijacked by the virus, many of which are druggable targets (29) . Chemoinformatics approaches and literature search by experts highlighted 69 compounds that target 62 proteins found in the PPI network. Translation inhibitors and molecules that target sigma-1 and sigma-2 receptors emerged as effective antiviral candidates in vitro. The translation inhibitor plitidepsin was subsequently characterized as a potent antiviral in vitro and in vivo with ;30-fold-higher efficacy than remdesivir (108). Watanabe et al. generated an influenza-human protein interaction network via mass spectrometry and targeted the host factors with small interfering RNAs (siRNAs) to identify those involved in viral replication (109) . Querying various drug databases for chemicals targeting these host factors led to the identification of 61 drugs, where further experimental studies highlighted GBF1 inhibitor golgicide A and JAK1 inhibitor ruxolitinib as viable candidates for anti-influenza therapy. Phosphoproteomics approaches (110) have also been successfully used to identify druggable host factors, especially those targeted by kinase inhibitors, which were shown to have antiviral effects against various viruses (111) . Dynamics of kinase activity can be inferred computationally following characterization of sites phosphorylated upon infection, and kinases whose activity can explain virus-associated changes in phosphosites are then linked to drugs modulating their activity. This strategy has been applied to various viruses, which led to the nomination of GRK2 inhibitors for influenza (112) , JNK1 inhibitors for Japanese encephalitis virus (113) , and various inhibitors targeting casein kinase II, p38/MAPK (mitogenactivated protein kinase) signaling, and growth factor receptor signaling for SARS-CoV-2 (61, 114) treatment.

Network-based approaches have also been crucial for nominating drug repurposing candidates by integrating virus-host protein interaction, human protein-protein interaction, and drug-target interaction networks. One key idea behind these approaches is to consider interactions between host factors within a human PPI network and the downstream effects that dysregulation of a protein could cause based on these relationships. These integrative approaches can reveal indirect effects of proteins hijacked by viruses, and searching for drugs that can modulate these downstream effects can present additional druggable opportunities. Network-based studies have especially been valuable for SARS-CoV-2 research, offering resources to identify putative antiviral therapy options in a timely manner. For instance, the study by Zhou et al. generated a coronavirus-host interaction network by integrating various experimental resources that characterized interactions of six different viruses, including SARS-CoV-1 and Middle East respiratory syndrome (MERS)-CoV, to assemble the set of human proteins associated with these viruses (115) . This study also generated a drug-target interaction network obtained from various drug databases exemplified above. To identify drugs with the potential to target SARS-CoV-2, Zhou et al. (115) used a "network proximity measure," which computes distances between the host factors and proteins targeted by a given drug based on the human PPI network's connectivity and prioritizes drugs whose targets are in close proximity to the host factors.

In another network-based study, Gysi et al. (116) implemented 12 different pipelines that rely on network proximity, network diffusion, and artificial intelligence principles, where they searched for drugs that can target the network of SARS-CoV-2 interactors identified by Gordon et al. (29) . Proximity-based approaches focused on the distance between SARS-CoV-2 interactors and targets of drugs to rank drugs based on proximity scores, whereas diffusion methods ranked them based on the network similarity of drug targets and SARS-CoV-2 targets. Graph neural networks were implemented for artificial intelligence-based approaches. After characterizing the results of each individual method, the authors used a multimodal approach to combine different pipelines' rankings together to generate a consensus list of predictions, taking advantage of the strengths of each individual pipeline. Sadegh et al.'s work offers researchers the opportunity to explore a virus-host interaction network from a drug target identification perspective by developing an online tool called CoVex (Coronavirus Explorer) that provides visualization of virus-host networks, drugs, and their targets (117, 118) . They also implemented various network-based algorithms that can build bridges between host factors through neighboring, related proteins and connect these proteins to drugs targeting them, such as multi-Steiner tree, closeness centrality, and degree centrality. Currently, this resource includes PPI networks for SARS-CoV-1 (119, 120) and SARS-CoV-2 (29) with plans to add networks for additional viruses, and it allows the researchers to run custom queries that can start from viral or host proteins of interest to identify a set of drugs that can target them directly or indirectly generating actionable hypotheses on drug repositioning.

Studies highlighted here focused on drug repurposing strategies that have been applied to virus-associated data sets to underscore the utility of these algorithms in identifying antiviral therapies. For additional information on alternative repurposing approaches with a broader scope, we refer readers to several reviews that discuss properties of different algorithms and how various omics technologies and data sources are used for network-based drug repurposing (121) (122) (123) (124) . Application of these currently available drug repurposing algorithms or development of new approaches specifically tailored for viral proteomics data sets have the potential to identify viable targets for designing effective host-directed antiviral therapies both for viruses that currently lack effective treatments and emergent pathogens.

Drug repurposing studies we discussed up to now have mostly focused on a single virus and characterizing its set of druggable targets. However, when we compare characteristics of different viruses, commonalities between proteins and biological processes that they interact with start to emerge, raising the possibility of identifying druggable host factors shared across multiple viruses (125) . These comparisons could focus on a single family and characterize a set of related viruses in detail while taking their sequence homology and evolutionary differences into account. One such study comparing PPI networks of three coronaviruses revealed the set of interactions that are conserved across the three and trends that are shared between more closely related SARS-CoV-1 and SARS-CoV-2 but not identified in MERS-CoV (126) . Drugs targeting proteins shared across viruses were also discussed to exemplify how these networks can be used to discover drugs that can be effective against multiple pathogens. Examples of other comparative analyses include ones that go beyond a single family, such as the study by Pichlmair et al., where they characterized human proteins interacting with 70 viral proteins from 30 different viruses using AP-MS (127) and the study by Bösl et al., which built an interaction network of 17 viruses by curating AP-MS and yeast two-hybrid studies (128) . Focusing on a broader range of viruses revealed shared biological processes across distinct viruses that illustrate pathways crucial for viral infection and enabled comparisons between different groups of viruses, such as minus-strand single-stranded RNA [ssRNA (2) ], plus-strand ssRNA [ssRNA(1)], doublestranded RNA (dsRNA), and double-stranded DNA (dsDNA) viruses. Additionally, Bösl et al. (128) queried DGIdb to identify drugs targeting proteins within this host-virus interaction network, highlighting putative pan-viral therapy options. Cataloging processes that are unique to individual viruses or shared across viruses will generate a valuable resource as we move forward with the design of host-directed antiviral therapies. It will help prioritize drug repurposing opportunities with the potential to be effective broad-acting antivirals and match a specific set of drugs to the most relevant group of viruses based on the intersection between their targets and shared host factors.

Proteomics and systems biology approaches are strikingly suited to provide a rapid and useful functional landscape of host-virus interactions. While requiring cross discipline expertise, the current available pipelines using these methods can identify important host factors involved in viral replication. Such insights are critical to develop efficient host-targeted antiviral therapies by allowing us to quickly nominate targetable host functions using repurposed drugs or by developing new compounds able to inhibit specific host-virus protein complex formation or activity. Importantly, as the description of different virus interactions with their host partner grows, it becomes clear that commonalities could be identified and exploited to target essential host factors shared by several viruses.

Infectious disease threats in the twentyfirst century: strengthening the global response

mRNA vaccines -a new era in vaccinology

Beigel JH, mRNA-1273 Study Group. 2020. An mRNA vaccine against SARS-CoV-2 -preliminary report

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses

2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Viral emerging diseases: challenges in developing vaccination strategies

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Innovation and trends in the development and approval of antiviral medicines

Antiviral drug resistance as an adaptive process

Drug resistance in antiviral therapy

CRISPR genetic screens to discover host-virus interactions

CRISPR-Cas9 genetic analysis of virus-host interactions

Protein-protein interactions in virus-host systems

New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections

Host-directed antiviral therapy

Virus-host interactions: new insights and advances in drug development against viral pathogens

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection

Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance

Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways

Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model

Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

A systems approach to infectious disease

Proteomic approaches to study SARS-CoV-2 biology and COVID-19 pathology

Mass spectrometry-based protein-protein interaction networks for the study of human diseases

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

BioID combined with mass spectrometry to study herpesvirus protein-protein interaction networks

Global interactomics uncovers extensive organellar targeting by Zika virus

The interactome of EBV LMP1 evaluated by proximity-based BioID approach

Affinity purification-mass spectroscopy methods for identifying Epstein-Barr virus-host interactions

Proteomic analysis of HIV-1 Gag interacting partners using proximity-dependent biotinylation

A targeted spatial-temporal proteomics approach implicates multiple cellular trafficking pathways in human cytomegalovirus virion maturation

Tracking and elucidating alphavirus-host protein interactions

Identification of cellular interaction partners of the influenza virus ribonucleoprotein complex and polymerase complex using proteomic-based approaches

Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport

Global landscape of HIV-human protein complexes

HIV-host interactome revealed directly from infected cells

Mass spectrometry-based proteomic analysis of the epitope-tag affinity purified protein complexes in eukaryotes

Creating collaboration by breaking down scientific barriers

Cross-linking mass spectrometry: an emerging technology for interactomics and structural biology

Identification of subunit-subunit interactions in bacteriophage P22 procapsids by chemical cross-linking and mass spectrometry

Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasion

Proximity labeling: spatially resolved proteomic mapping for neurobiology

Recent advances in proximity-based labeling methods for interactome mapping. F1000Res 8:F1000 Faculty Rev-135

A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells

An improved smaller biotin ligase for BioID proximity labeling

Efficient proximity labeling in living cells and organisms with TurboID

Engineered ascorbate peroxidase as a genetically encoded reporter for electron microscopy

Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging

Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2

An approach to spatiotemporally resolve protein interaction networks in living cells

Role of host-mediated post-translational modifications (PTMs) in RNA virus pathogenesis

The role of the host ubiquitin system in promoting replication of emergent viruses

Post-translational regulation of antiviral innate signaling

Post-translational modification control of innate immunity

Interplay between viruses and host sumoylation pathways

Crosstalk between SUMO and ubiquitin-like proteins: implication for antiviral defense

The global phosphorylation landscape of SARS-CoV-2 infection

Dynamic remodelling of the human host cell proteome and phosphoproteome upon enterovirus infection

An orthogonal proteomic survey uncovers novel Zika virus host factors

Phosphopeptide enrichment for phosphoproteomic analysis -a tutorial and review of novel materials

Advances in phosphopeptide enrichment techniques for phosphoproteomics

Enrichment techniques employed in phosphoproteomics

Large-scale discovery of substrates of the human kinome

The functional landscape of the human phosphoproteome

Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring

Proteomic profiling of HIV-1 infection of human CD4 T cells identifies PSGL-1 as an HIV restriction factor

TRIM32 senses and restricts influenza A virus by ubiquitination of PB1 polymerase

Orchestration of protein acetylation as a toggle for cellular defense and virus replication

Ubiquitin-modified proteome of SARS-CoV-2-infected host cells reveals insights into virus-host interaction and pathogenesis

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV

Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

SARS-CoV-2 infection remodels the host protein thermal stability landscape

Temporal dynamics of protein complex formation and dissociation during human cytomegalovirus infection

The cellular thermal shift assay for evaluating drug target interactions in cells

Exploring and exploiting proteome organization during viral infection

A draft map of the mouse pluripotent stem cell spatial proteome

Global, quantitative and dynamic mapping of protein subcellular localization

Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth

A high-density human mitochondrial proximity interaction network

The human cytoplasmic dynein interactome reveals novel activators of motility

Recycling of Golgi glycosyltransferases requires direct binding to coatomer

Heterogeneous translational landscape of the endoplasmic reticulum revealed by ribosome proximity labeling and transcriptome analysis

Cross-linking/mass spectrometry to get a closer view on protein interaction networks

Structural investigation of proteins and protein complexes by chemical cross-linking/mass spectrometry

Interaction interface of Mason-Pfizer monkey virus matrix and envelope proteins

Structure of the gene therapy vector, adeno-associated virus with its cell receptor

Cross-linking immunoprecipitation-MS (xIP-MS): topological analysis of chromatin-associated protein complexes using single affinity purification

Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments

Hydrogen exchange mass spectrometry for studying protein structure and dynamics

Using hydrogen-deuterium exchange mass spectrometry to examine protein-membrane interactions

Conformational insight into multi-protein signaling assemblies by hydrogen-deuterium exchange mass spectrometry

Hydrogen-exchange mass spectrometry for the study of intrinsic disorder in proteins

Differential hydrogen/deuterium exchange mass spectrometry analysis of proteinligand interactions

Protein structure change studied by hydrogendeuterium exchange, functional labeling, and mass spectrometry

Drug repurposing: progress, challenges and recommendations

Drug repositioning: identifying and developing new uses for existing drugs

Drug databases and their contributions to drug repurposing

DrugBank 5.0: a major update to the DrugBank database

Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts

ChEMBL: towards direct deposition of bioassay data

Pharmacogenomics knowledge for personalized medicine

Novel insights into human respiratory syncytial virus-host factor interactions through integrated proteomics and transcriptomics analysis

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Influenza virus-host interactome screen as a platform for antiviral drug development

Phosphoproteomics in drug discovery

Repurposing of kinase inhibitors as broad-spectrum antiviral drugs

Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target

Quantitative phosphoproteomic analysis identifies the critical role of JNK1 in neuroinflammation induced by Japanese encephalitis virus

Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication

Networkbased drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Network medicine framework for identifying drug repurposing opportunities for COVID-19

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

Individuating possibly repurposable drugs and drug targets for COVID-19 treatment through hypothesis-driven systems medicine using CoVex

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

VirHostNet 2.0: surfing on the web of virus/host molecular interactions data

A review of network-based approaches to drug repositioning

A paradigm shift in medicine: a comprehensive review of network-based approaches

Network-based drug repositioning

Network-based drug repositioning: approaches, resources, and research directions

New horizons for antiviral drug discovery from virus-host protein interaction networks

Comparative host-coronavirus protein interaction networks reveal panviral disease mechanisms

Viral immune modulators perturb the human molecular network by common and unique strategies

Common nodes of virus-host interaction revealed through an integrated network analysis

We thank Manon Eckhardt for her valuable comments. This work was funded by grants from the National Institutes of Health (P50AI150476, U19AI135972, and R01AI143292); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between University of California, San Francisco (UCSF), University of California, Berkeley (UCB), and GSK (133122P); by funding from F. Hoffmann-La Roche and Vir Biotechnology, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-19-2-0020.The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government.The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. Nevan Krogan has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, and Interline Therapeutics. He is a shareholder in Tenaya Therapeutics, Maze Therapeutics, and Interline Therapeutics.